Literature DB >> 9829727

Inhibition of tumor growth by a dominant negative mutant of the insulin-like growth factor I receptor with a bystander effect.

K Reiss1, C D'Ambrosio, X Tu, C Tu, R Baserga.   

Abstract

The insulin-like growth factor I receptor is known to play a major role in transformation and apoptosis. The dominant negative mutant of the insulin-like growth factor I receptor, designated 486/STOP, causes massive apoptosis of tumor cells and inhibition of tumor growth and metastases. We now show that: (a) the stable expression of 486/STOP inhibits transformation (colony formation in soft agar) and/or tumor growth in nude mice of five different types of human tumor cell lines; and (b) more importantly, it has a bystander effect, inhibiting the growth of wild-type tumor cells when cells expressing 486/STOP are coinjected with wild-type tumor cells. These findings suggest that it is not necessary to infect all tumor cells with 486/STOP to inhibit tumor growth, and they also open the possibility of using the product of 486/STOP directly against tumor cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9829727

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  18 in total

1.  Bone-derived IGF mediates crosstalk between bone and breast cancer cells in bony metastases.

Authors:  Toru Hiraga; Akira Myoui; Nobuyuki Hashimoto; Akira Sasaki; Kenji Hata; Yoshihiro Morita; Hideki Yoshikawa; Clifford J Rosen; Gregory R Mundy; Toshiyuki Yoneda
Journal:  Cancer Res       Date:  2012-06-27       Impact factor: 12.701

Review 2.  Role of insulin-like growth factor-1R system in colorectal carcinogenesis.

Authors:  Erin A Donovan; Shivaani Kummar
Journal:  Crit Rev Oncol Hematol       Date:  2007-10-31       Impact factor: 6.312

3.  Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis.

Authors:  F Peruzzi; M Prisco; M Dews; P Salomoni; E Grassilli; G Romano; B Calabretta; R Baserga
Journal:  Mol Cell Biol       Date:  1999-10       Impact factor: 4.272

Review 4.  IGF-I receptor signalling in transformation and differentiation.

Authors:  B Valentinis; R Baserga
Journal:  Mol Pathol       Date:  2001-06

Review 5.  New developments in targeted therapy for soft tissue sarcoma.

Authors:  Kristen N Ganjoo
Journal:  Curr Oncol Rep       Date:  2010-07       Impact factor: 5.075

Review 6.  Cancer cell survival during detachment from the ECM: multiple barriers to tumour progression.

Authors:  Cassandra L Buchheit; Kelsey J Weigel; Zachary T Schafer
Journal:  Nat Rev Cancer       Date:  2014-08-07       Impact factor: 60.716

7.  Degradation and dephosphorylation of focal adhesion kinase during okadaic acid-induced apoptosis in human neuroblastoma cells.

Authors:  Bhumsoo Kim; Cynthia M van Golen; Eva L Feldman
Journal:  Neoplasia       Date:  2003 Sep-Oct       Impact factor: 5.715

8.  Inducible expression of dominant negative insulin-like growth factor I receptor in MCF-7 breast cancer cells.

Authors:  Geetanjalee Modha; Anne Blanchard; Janine Sidorchuk; Marcello Venditti; Robert Shiu; Yvonne Myal
Journal:  Endocrine       Date:  2003-12       Impact factor: 3.633

Review 9.  Growth factor signalling in prostatic growth: significance in tumour development and therapeutic targeting.

Authors:  Arich Ryan Reynolds; Natasha Kyprianou
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

10.  Neuroendocrine-derived peptides promote prostate cancer cell survival through activation of IGF-1R signaling.

Authors:  John O DaSilva; George P Amorino; Eli V Casarez; Bradley Pemberton; Sarah J Parsons
Journal:  Prostate       Date:  2012-11-28       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.